CCC
ZBH icon

Crescent Capital Consulting’s Zimmer Biomet ZBH Stock Holding History

Crescent Capital Consulting’s Portfolio ZBH Stock Details ZBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$8K Hold
62
– – ﹤0.01% 412
2021
Q3 		$9K Sell
62
-23
-27% -$3.38K ﹤0.01% 434
2021
Q2 		$14K Buy
85
+23
+37% +$3.73K ﹤0.01% 351
2021
Q1 		$10K Hold
62
– – ﹤0.01% 390
2020
Q4 		$9K Buy
+62
New +$8.76K ﹤0.01% 359

Other funds holding ZBH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Crescent Capital Consulting's ZBH Position: Q4 2021 in Review

Crescent Capital Consulting held its Zimmer Biomet (ZBH) position steady in Q4 2021 at 62 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #412.

Crescent Capital Consulting first reported a position in ZBH in Q4 2020 and has held it in 5 quarters since. The position peaked at $14K in Q2 2021. 998 funds tracked by Wall St. Rank hold ZBH as of Q4 2021.

  • Crescent Capital Consulting held 62 shares of Zimmer Biomet worth $8K as of Q4 2021.
  • Crescent Capital Consulting left its Zimmer Biomet share count unchanged in Q4 2021.
  • Zimmer Biomet made up ﹤0.01% of Crescent Capital Consulting's portfolio in Q4 2021, its #412 holding.
  • Crescent Capital Consulting first reported a position in Zimmer Biomet in Q4 2020 and has held it in 5 quarters since.
  • Crescent Capital Consulting's Zimmer Biomet position peaked at $14K in Q2 2021.
  • 998 funds tracked by Wall St. Rank held Zimmer Biomet as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.